https://www.selleckchem.com/products/peg300.html
MiR-429 inhibits the progression of PDAC cells by regulating EMT. Our study provided a novel potential mechanism for the occurrence of PDAC and laid the foundation for the development of miRNA targeted therapy in patients with PDAC. This study aimed to observe the efficacy of continuous i.v. infusion of Recombinant Human Vascular Endothelial Growth Inhibitor (rhVEGI) in combination with chemotherapy in patients with advanced lung cancer (ALC). Eighty-six patients with ALC treated at our hospital between November 2018 and May 2020 were di
Curtir
Comentario
Compartilhar
